Next Article in Journal
Modern Trends in Natural Antibiotic Discovery
Next Article in Special Issue
Chronological Changes of Lower Urinary Tract Symptoms in Elderly Patients with Prostate Cancer after Low-Dose-Rate Prostate Brachytherapy
Previous Article in Journal
The Effects of Humic Acids on the Early Developmental Stages of African Cichlids during Artificial Breeding
Previous Article in Special Issue
Learning Curve of Transperineal MRI/US Fusion Prostate Biopsy: 4-Year Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 13
Issue 5
10.3390/life13051072
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer

by
Fumiya Sugino
1,
Keita Nakane
1,
Makoto Kawase
1,
Shota Ueda
2,
Masayuki Tomioka
3,
Yasumichi Takeuchi
4,
Risa Tomioka-Inagawa
1,
Toyohiro Yamada
1,
Sanae Namiki
1,
Naotaka Kumada
1,
Shinichi Takeuchi
1,
Kota Kawase
1,
Daiki Kato
1,
Manabu Takai
1,
Koji Iinuma
1,
Yuki Tobisawa
5 and
Takuya Koie
1,*
1
Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan
2
Department of Urology, Japanese Red Cross Takayama Hospital, Takayama 5068550, Japan
3
Department of Urology, Chuno Kosei Hospital, Seki 5013802, Japan
4
Department of Urology, Japanese Red Cross Gifu Hospital, Gifu 5028511, Japan
5
Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki 0358562, Japan
*
Author to whom correspondence should be addressed.
Life 2023, 13(5), 1072; https://doi.org/10.3390/life13051072
Submission received: 22 March 2023 / Revised: 21 April 2023 / Accepted: 21 April 2023 / Published: 23 April 2023
(This article belongs to the Special Issue Prostate Cancer: 2nd Edition)
Browse Figures
Versions Notes

Abstract

Background: This retrospective single-center cohort study evaluated the efficacy and safety of a combination of neoadjuvant luteinizing hormone-releasing hormone (LHRH) antagonist and tegafur-uracil (UFT) therapy (NCHT) and investigated the medical records of patients with high-risk PCa who underwent robot-assisted radical prostatectomy (RARP). The therapy was followed by RARP for high-risk PCa. Materials and Methods: The enrolled patients were divided into two groups: low-intermediate-risk PCa patients who underwent RARP without neoadjuvant therapy (non-high-risk) and those who underwent NCHT followed by RARP (high-risk group). This study enrolled 227 patients (126: non-high-risk and 101: high-risk group). Patients in the high-risk-group had high-grade cancer compared to those in the non-high-risk-group. Results: At the median follow-up period of 12.0 months, there were no PCa deaths; two patients (0.9%) died of other causes. Twenty patients developed biochemical recurrence (BCR); the median time until BCR was 9.9 months after surgery. The 2-year biochemical recurrence-free survival rates were 94.2% and 91.1% in the non-high-risk and high-risk-group, respectively (p = 0.465). Grade ≥3 NCHT-related adverse events developed in nine patients (8.9%). Conclusions: This study indicates that combining neoadjuvant LHRH antagonists and UFT followed by RARP may improve oncological outcomes in patients with high-risk PCa.
Keywords: high-risk prostate cancer; robot-assisted radical prostatectomy; neoadjuvant chemohormonal therapy; luteinizing hormone-releasing hormone antagonist; tegafur-uracil high-risk prostate cancer; robot-assisted radical prostatectomy; neoadjuvant chemohormonal therapy; luteinizing hormone-releasing hormone antagonist; tegafur-uracil

Share and Cite

MDPI and ACS Style

Sugino, F.; Nakane, K.; Kawase, M.; Ueda, S.; Tomioka, M.; Takeuchi, Y.; Tomioka-Inagawa, R.; Yamada, T.; Namiki, S.; Kumada, N.; et al. Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer. Life 2023, 13, 1072. https://doi.org/10.3390/life13051072

AMA Style

Sugino F, Nakane K, Kawase M, Ueda S, Tomioka M, Takeuchi Y, Tomioka-Inagawa R, Yamada T, Namiki S, Kumada N, et al. Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer. Life. 2023; 13(5):1072. https://doi.org/10.3390/life13051072

Chicago/Turabian Style

Sugino, Fumiya, Keita Nakane, Makoto Kawase, Shota Ueda, Masayuki Tomioka, Yasumichi Takeuchi, Risa Tomioka-Inagawa, Toyohiro Yamada, Sanae Namiki, Naotaka Kumada, and et al. 2023. "Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer" Life 13, no. 5: 1072. https://doi.org/10.3390/life13051072

APA Style

Sugino, F., Nakane, K., Kawase, M., Ueda, S., Tomioka, M., Takeuchi, Y., Tomioka-Inagawa, R., Yamada, T., Namiki, S., Kumada, N., Takeuchi, S., Kawase, K., Kato, D., Takai, M., Iinuma, K., Tobisawa, Y., & Koie, T. (2023). Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer. Life, 13(5), 1072. https://doi.org/10.3390/life13051072

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop